Purpose: Measurements of non-displaceable binding (V ND ) of positron emission tomography (PET) ligands are not often made in vivo in humans because they require ligands to displace binding to target receptors and there are few readily available, safe ones to use. A technique to measure V ND for ligands for the 18-kDa translocator protein (TSPO) has recently been developed which compares the total volume of distribution (V T ) before and after administration of the TSPO ligand XBD173. Here, we used XBD173 with an occupancy plot to quantify V ND for two TSPO radiotracers, [ C]PBR28 PET (n = 6; three HAB, three MAB each). Arterial blood sampling was used to generate plasma input functions for the two-tissue compartment model. V ND was calculated using two independent methods: the occupancy plot (by modelling the differences in signal post XBD173) and the polymorphism plot (by modelling the differences in signal across presence and absence of rs6971 genotypes). Results: Whole brain V T (mean ± standard deviation) was 0. 
Introduction
Several positron emission tomography (PET) ligands exist for the 18-kDa translocator protein (TSPO), which can be upregulated in the mitochondria of activated microglia when the central nervous system becomes inflamed (see [1] for review). Currently, it is unclear, in humans, what proportion of the observed in vivo PET signal represents specific TSPO binding and what proportion is merely non-displaceable binding. This is a particular problem with TSPO imaging as (1) the binding of a large majority of TSPO ligands is affected by carriage of a single nucleotide polymorphism (SNP rs6971) and (2) affinity thus varies according to whether participants are homozygotic (high or low affinity binders, HABs/LABs) or heterozygotic (mixed affinity binders, MABs). This results in increased tracer-specific variability across cohorts [2] . TSPO is known to be expressed ubiquitously throughout the human brain, meaning that there is no suitable reference region (free of specific binding) which would allow the nondisplaceable proportion of the signal to be estimated in vivo (see [3] for overview). Assuming that the fraction of non-displaceable binding is negligible can dramatically affect the interpretation of results. It is therefore important to investigate the proportion of binding that is specific for each TSPO tracer [4, 5] .
Approaches recently described by Owen et al. [6] and Guo et al. [7] can be used to estimate the non-displaceable component of the total volume of distribution (V ND ) in vivo. In short, for the TSPO ligand of interest, the total volume of distribution, V T , is calculated both before and after blockade with the TSPO ligand XBD173. V ND is derived from the xintercept of the graph of V (see 'Materials and Methods'). In addition, use of a polymorphism plot (Guo, et al. [8] ), which assumes that MABs express an equal percentage of high and low affinity binding sites [6, 9] , allows V ND to be derived from the x-intercept of V One recently developed ligand, [ 18 F]GE-180, has exhibited a higher signal to background ratio than (R)-[ 11 C]PK11195 in several preclinical models [10] [11] [12] . However, in human studies, it has shown unexpectedly low brain penetration [13] [14] [15] . Additionally, in vitro data shows that binding of [ 18 F]GE-180 to TSPO is sensitive to the presence of the rs6971 SNP [2, 9, 16] ; however, in these in vivo human studies, the expected genotype dependence of signals was not observed [13, 14] . This phenomenon may be due to poor extraction of [ 18 F]GE-180 over the blood−brain barrier (BBB) and/or the action of active efflux pumps such as P-glycoprotein. Given these unexpected results, we wished to clarify the proportion of [
18 F]GE-180 uptake detected with PET in the human brain that is non-displaceable. A recent blocking study in healthy control subjects confirmed the presence of specific binding throughout the human brain with [ 11 C]PBR28 [6] . Here, we describe a similar blocking study to investigate whether (and what proportion of) [ 18 F]GE-180 and [ 11 C]PBR28 PET signal is specific to TSPO binding in people with multiple sclerosis (MS).
Materials and Methods

Participants
Twelve people with clinically definite MS according to revised 2010 MacDonald criteria were recruited from the Imperial College Healthcare NHS Trust. The participants were aged between 20 and 50 11 C]PBR28, participants returned for a 'postblockade' scan; they were administered a 90-mg oral dose of XBD173 2 h prior to a repeat PET scan with the same tracer and dose as previously administered. The dose of 90 mg was selected based on that previously calculated by Owen et al. in a blocking study using [ 11 C]PBR28 to achieve at least 75 % XBD173 occupancy in adult participants [6] .
Arterial Plasma Measurement
Participants had radial artery cannulation and blood was withdrawn continuously at a target rate of 2.5 ml min [6] were used to determine the parent fraction of tracer in plasma and whole blood.
Scanning Protocol
All participants scanned with [ 18 F]GE-180 underwent MR scans on a 3-T Siemens Magnetom MR B19 scanner, including T1 magnetisation prepared rapid gradient echo (MPRAGE) sequences. [ 18 F]GE-180 was synthesised, as previously described, on a FastLab™ platform [18] . A lowdose CT scan was performed for attenuation correction immediately prior to a 90-min dynamic PET scan on a Siemens Biograph 6 with a field of view of 168 × 168 × 148 mm 3 . The tracer was injected as an intravenous bolus over the course of 30 s with a target dose of 185 MBq. Listmode data were histogrammed into 24 frames (6 × 15 s, 3 × 60 s, 5 × 120 s, 5 × 300 s and 5 × 600 s) and reconstructed using filtered back projection (FBP) with a ramp filter. Reconstructed voxel size and spatial resolution were 1.57 × 1.57 × 1.92 and~5 mm, respectively. For participants scanned with [ 11 C]PBR28, MR scans were performed on a Siemens Magnetom Trio scanner, while PET scans were also performed on a Siemens Biograph 6, with list-mode data histogrammed into 26 frames (8 × 15 s, 3 × 60 s, 5 × 120 s, 5 × 300 s and 5 × 600 s) and reconstructed using FBP with a 5-mm Gaussian filter. For [
18 F]GE-180 scans, the tracer was injected 30 s after scan start time (two fewer frames in the reconstruction).
Image Analysis
PET images underwent frame-to-frame realignment and were coregistered with T1 MRI in PMOD (v3.6, PMOD Technologies Ltd., Switzerland). Coregistrations were quality checked manually. MRI was used to segment the brain into 83 regions using the Hammers atlas [19] . These regions were inspected manually for overlap and edited where necessary to minimise spillover from large-vessel vascular activity. Respective smaller ROIs were then combined to create final bilateral ROIs as follows: frontal, temporal, parietal and occipital lobes (FL, TL, PL, OL), striatum, putamen, thalamus, cerebellum, corpus callosum, brainstem, whole brain (WB) and normal appearing white matter (NAWM). Lesions were defined semi-automatically on MRI using a local thresholding technique implemented in in-house software (BioMedIA group, Department of Computing, Imperial College London). T1, T2 fluid attenuated inversion recovery (FLAIR), double inversion recovery (DIR) and phase sensitive inversion recovery (PSIR) sequences were used to maximise sensitivity of lesion identification. All ROIs excluded lesions.
Kinetic Analysis
All kinetic analysis was performed in PMOD. Calibrated continuous and discrete blood data were corrected for decay and the parent fraction of tracer in plasma was calculated for each discrete sample. Plasma over blood (POB) ratios were calculated and the parent fraction of tracer in plasma fitted to a Watabe parent fraction model [20] of the form
, where f p is the free fraction of parent tracer and A, B, C and u are constants. This was multiplied with the continuous whole blood data to produce a metabolite-corrected arterial plasma input function. V T was calculated from the unconstrained two-tissue compartment model as previously described [13, 14] .
Calculating the Component of Non-Displaceable Binding
Three methods were used to determine the non-displaceable (V ND ) and displaceable (V S ) components of the total volume of distribution (V T ). Of these methods, two were independent: the occupancy plot (methods 1a and 1b) and the polymorphism plot (method 2).
Method 1a: Occupancy Plot with Individual V ND
The occupancy plot is an adaptation of the Lassen plot described by Cunningham et al. [4] . Given that
allows derivation of V ND (xintercept) and the occupancy of XBD173 (slope). This method assumes that V ND is the same at pre and post-block time points and that the fractional occupancy of XBD173 does not change across the brain. Method 1a plots these data for each individual participant.
Method 1b: Occupancy Plot with Constrained V ND
In order to calculate a group V ND , data from individual participants were plotted as described in method 1a, with the x-intercept forced to a best fit for all participants. This was done by constraining the x-intercept (V ND ) to be equal (for all participants) on a group level, using a linear regression implemented in Matlab (R2018a, The MathWorks, Inc., MA, USA).
Method 2: Polymorphism Plot
The polymorphism plot, described by Guo et al. [7] , does not require pharmacological blockade. Instead, it relies upon the assumption that MABs express 50 % HAB and 50 % LAB binding sites [6, 9] . Thus, similarly to methods 1a and 1b, V 
Statistics
Linear regressions were generated in Matlab (R2018a, The MathWorks, Inc., MA, USA) and V T and V ND results are expressed as mean ± standard deviation (SD). For each tracer, V T s in different ROIs were compared using repeated measures one-way ANOVA with a Tukey test for multiple comparisons. Statistical tests were performed in GraphPad Prism (v7, GraphPad Software, Inc., San Diego, CA, USA). 
Results
Demographics
Specific Binding to TSPO Is Ubiquitous in the MS Brain
For [
18 F]GE-180, V S accounted for between 39 % (striatum) and 54 % (thalamus) of total binding in the selected ROIs (mean ± SD, 45 ± 5 %). For [
11 C]PBR28, V S accounted for between 6 % (striatum) and 43 % (brainstem) of total binding (29 ± 11 %). All other ROIs defined by the Hammers atlas, including the caudate and non-cortical GM, exhibited mean V T between 0.25 and 0.56 ml/cm 3 and between 3.99 and 7.39 ml/cm 3 , respectively. Thus, it follows that no ROIs were consistently devoid of specific TSPO binding, as measured by either tracer.
Discussion
This study was designed to quantify the non-specific binding ( with relapsing-remitting MS [24] , but questions remain as to whether this increase in signal represents specific binding or is merely due to non-specific signal in areas of blood−brain barrier breakdown. Another recent study which directly compared [
18 F]GE-180 with [ 11 C]PBR28 in healthy controls who were scanned with both tracers (morning and afternoon) found up to 20 times lower volumes of distribution with the former compared to the latter [15] as well as difficulties with [ 18 F]GE-180 quantification. To our knowledge, ours is the first study assessing non-displaceable binding of [
18 F]GE-180 and comparing both tracers in disease cohorts. Our results argue that, despite low brain penetration [13, 14] , [ 18 F]GE-180 does exhibit a specific signal in the MS brain and hence could be useful in conditions with pathologically increased levels of TSPO. We also performed gadolinium contrast-enhancing MRI in the cohort of participants scanned with [ 18 F]GE-180 and observed no contrast enhancement (in lesion areas or otherwise), suggesting no extensive BBB breakdown. Although this observation does not exclude the possibility of micro-BBB breakdown, which could allow passage of [ 18 F]GE-180 molecules, but not the larger gadolinium molecules, through the disrupted area, the finding does concur with that of Vomacka et al. [25] . The authors of this study also comment that (in their previous study [23] ) areas with contrast enhancement in MR did not always correlate with increased [ 18 F]GE-180 signal, indicating that signal increases in PET are likely to be related to TSPO expression rather than exclusively BBB breakdown. The results also have broader implications on how novel tracers should be validated and compared. While high absolute V T s are preferable in a tracer, it is crucial to understand what proportion of V T is driven by V ND . This can be achieved using a blocking study, which, given the lack of an appropriate receptor-free reference region in the brain, we suggest should be undertaken for all TSPO tracers undergoing clinical development.
Although the occupancy plot has been more commonly used in V ND quantification [4] , an alternative approach, relevant for TSPO tracers which are susceptible to the rs6971 SNP, is to create a polymorphism plot, which does not require pharmacological blockade and relies only on the assumption of equal expression of HAB and LAB sites. Our V ND results from both methods (including free and fixedintercept occupancy plots) were in good agreement for both tracers, giving an average V ND of 0.16 ± 0.05 ml/cm 3 for [ 18 F]GE-180 and 3.65 ± 0.16 ml/cm 3 for [ 11 C]PBR28. In this study, we also demonstrate that V T is consistently greater than V ND for both [ 18 F]GE-180 and [ 11 C]PBR28; in other words, no ROIs were devoid of specific TSPO binding. This finding fits with previous observations that reference tissue approaches may not be appropriate in TSPO PET studies [6] .
[ 11 C]PBR28 has been validated with blocking experiments prior to our study, both in healthy controls [6, 26] and in a disease cohort [27] . [ 11 C]PBR28 is generally accepted as an effective TSPO tracer in vivo [28] [29] [30] [31] [32] although exhibits counterintuitively decreased V T in subjects with neuroinflammation [29] . In Owen et al. [6] , the V ND of [ 11 C]PBR28 was 1.98 ml/cm 3 (~50 % of V T ), while Fujita et al. [26] reported an average V T of 4.3 ml/cm 3 (in HABs) and a BP ND of 1.2, giving a very similar V ND of 1.98 ml/cm 3 (~45 % of V T ). In our study, V ND for [
11 C]PBR28 was 3.65. It is possible that this is a disease-specific difference, given that both the former studies were performed in healthy subjects; however, the sample size in our study was also small and the estimation of V ND may therefore be subject to some biological variability. Nevertheless, the proportion of non-specific binding for [
18 F]GE-180 is comparable to or even lower than that of [ 11 C]PBR28 (V ND~5 5 vs.~69 %, respectively), although absolute V T s are lower [6, 27] . This result further indicates that [
18 F]GE-180 is able to identify specific TSPO signal in the MS brain, in spite of low brain penetration. We also report respective HAB and MAB V S of 57 and 20 % for [ As has been pointed out previously, the brain penetration of [
18 F]GE-180 is very low in humans [13] [14] [15] . Our findings also showed low values of V T and K 1 , indicating low extraction of the tracer across the blood−brain barrier (K 1~0 .003 vs. 0.2 ml/cm 3 /min for [ 11 C]PBR28; i.e.,~60× lower). Zanotti-Fregonara and colleagues also noted difficulty in kinetic model fitting of [ 18 F]GE-180 data using the standard two-tissue compartment model with free blood volume parameter, which we used [15] . Here, however, we were able to fit the large majority of regions well, with R 2 comparable to those seen with [
11 C]PBR28 (R 2~0 .8) and standard errors on V T estimates G 20 % for both tracers. It is possible that this is due to the larger, less noisy ROIs selected for analysis in our study compared to those used by Zanotti-Fregonara and colleagues. Also to be considered is the fact that our study involved (six) participants with MS, compared to the four healthy controls and single participant with amytrophic lateral sclerosis in the other study, which may have resulted in altered binding kinetics due to diseasespecific pathology. Although a methodology considering large ROIs in a disease such as MS, with focal lesion-based pathology, may seem to limit the usefulness of a tracer, there is evidence that there is a global effect on TSPO PET signal in regions such as NAWM and normal appearing grey matter (see [33] for review), suggesting that [
18 F]GE-180 need not be excluded from use based on this fact. Many recent studies using [ 11 C]PBR28 (and other tracers) have elected to use the 2TCM-1K kinetic model [34] , which incorporates a parameter representing the endothelial fraction of binding of a TSPO tracer, for quantification [29] . The 2TCM-1K has been used with [ 18 F]GE-180 data [13] and has not shown a substantial advantage in terms of parsimony criteria (Akaike Information Criteria, AIC) compared to the 2TCM. Furthermore, [
11 C]PBR28 datasets are often still analysed using the 2TCM, primarily for comparison with data from other tracers [15, 35, 36] . We also found good fits to [ 11 C]PBR28 data with the 2TCM; thus, here, we elected to use this model to analyse data from both tracers.
The in vitro HAB/LAB ratio of binding affinity for [ 11 [13, 14, 24] , indicating that brain penetration of the tracer is low, except where BBB breakdown may be present [24] . Contrary to these results, in our study, HABs exhibited approximately twice the total volume of distribution of MABs in selected ROIs at baseline. It is likely that the difference in our study is driven primarily by one HAB with particularly high signal (participant D) and one MAB with particularly low signal (participant E). Clearly there is considerable variability in population V T and with the small sample size in our study (n = 6), we are unable to validate our findings with statistical tests. In addition, the difference in scan timing between the first and second (post-XBD173) scan varied for each tracer (half a day for [
11 C]PBR28 and 1 week for [
18 F]GE-180), which itself may have introduced some variability in PET signal. Thus, we suggest continuing binding status stratification of participants in future studies, where larger data pools may enable more reliable HAB/ MAB binding ratio estimates.
Several caveats exist in this study. Firstly, the occupancy of XBD173 in the two cohorts (slopes in the occupancy plots) varied between 24 and 95 % (fixedintercept plot) for [ 18 F]GE-180 and 16 and 220 % for [ 11 C]PBR28. Clearly, the occupancy of XBD173 cannot exceed 100 %, and indeed, the dose administered was precalculated to give an expected approximate 75 % occupancy, allowing for participant weights and considering the dose-occupancy relationship described by Owen et al. [6] for [ 11 C]PBR28. Of course, it should also be noted that these values were obtained from the fixed-intercept occupancy plot; for the free intercept plot, occupancies were within one standard deviation of the expected value. This point again highlights the large variability across cohorts and the fact that averaging results across participants, even within the same disease population, may not be a suitable approach. In addition, one participant scanned with [ 11 C]PBR28 exhibited no substantial occupancy and was excluded from further analysis. This large interindividual variability in occupancy was also seen in previous XBD173 blocking studies [6, 27] , reflected in the variability in total signal reduction (V T ) between pre and post-block scans. Whether driven by biological variability or experimental noise, these results provide evidence that V ND cannot necessarily be assumed to be the same across regions and a population. If there is indeed a biological spectrum of V ND between individuals, this raises the interesting possibility that blocking scans should be included for all participants in all TSPO PET studies to optimally quantify V S . This would have broad repercussions on TSPO PET study design, including cost, radiation exposure and participant discomfort. All neuro-PET tracers are, of course, better able to penetrate brain tissue when the BBB is disrupted. In the case of [
18 F]GE-180, which exhibits low penetration of the healthy BBB, this is particularly relevant. Although our cohorts were selected due to their clinically low or 'inactive' MRI, and although we investigated only lesion-free ROIs, we only performed contrast enhanced MRI to estimate BBB integrity in the [ 18 F]GE-180 cohort, and no measure of micro-BBB disruption was performed. Lastly, although this study was performed in a cohort of people with MS, we have not investigated how V T differs in MS lesions or how it correlates with clinical outcomes. This study was not powered to address these questions, since participants were not burdened with large lesion loads. Instead, these questions will be explored in follow-up studies.
Conclusion
In summary, pharmacological blockade with XBD173 demonstrates, for the first time in vivo, that [
18 F]GE-180 does bind specifically to TSPO in normal appearing white and grey matter, to an extent that is highly comparable to [ 11 C]PBR28, in spite of the low extraction fraction of the former.
